Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage

Stroke. 2009 Oct;40(10):3384-9. doi: 10.1161/STROKEAHA.108.544395. Epub 2009 Jul 30.

Abstract

Background and purpose: This study investigates the effects of statin treatment on experimental intracerebral hemorrhage (ICH) using behavioral, histological, and MRI measures of recovery.

Methods: Primary ICH was induced in rats. Simvastatin (2 mg/kg), atorvastatin (2 mg/kg), or phosphate-buffered saline (n=6 per group) was given daily for 1 week. MRI studies were performed 2 to 3 days before ICH, and at 1 to 2 hours and 1, 2, 7, 14, and 28 days after ICH. The ICH evolution was assessed via hematoma volume measurements using susceptibility-weighted imaging (SWI) and tissue loss using T2 maps and hematoxylin and eosin (H&E) histology. Neurobehavioral tests were done before ICH and at various time points post-ICH. Additional histological measures were performed with doublecortin neuronal nuclei and bromodeoxyuridine stainings.

Results: Initial ICH volumes determined by SWI were similar across all groups. Simvastatin significantly reduced hematoma volume at 4 weeks (P=0.002 versus control with acute volumes as baseline), whereas that for atorvastatin was marginal (P=0.09). MRI estimates of tissue loss (% of contralateral hemisphere) for treated rats were significantly lower (P=0.0003 and 0.001, respectively) than for control at 4 weeks. Similar results were obtained for H&E histology (P=0.0003 and 0.02, respectively). Tissue loss estimates between MRI and histology were well correlated (R2=0.764, P<0.0001). Significant improvement in neurological function was seen 2 to 4 weeks post-ICH with increased neurogenesis observed.

Conclusions: Simvastatin and atorvastatin significantly improved neurological recovery, decreased tissue loss, and increased neurogenesis when administered for 1 week after ICH.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Apoptosis / physiology
  • Atorvastatin
  • Biomarkers / analysis
  • Biomarkers / metabolism
  • Brain / blood supply
  • Brain / drug effects
  • Brain / pathology
  • Brain Infarction / drug therapy*
  • Brain Infarction / physiopathology
  • Brain Infarction / prevention & control
  • Bromodeoxyuridine
  • Cerebral Hemorrhage / drug therapy*
  • Cerebral Hemorrhage / metabolism
  • Cerebral Hemorrhage / physiopathology
  • Cytoprotection / drug effects
  • Cytoprotection / physiology
  • Diffusion Magnetic Resonance Imaging
  • Disease Models, Animal
  • Doublecortin Domain Proteins
  • Doublecortin Protein
  • Heptanoic Acids / therapeutic use*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Microtubule-Associated Proteins / analysis
  • Microtubule-Associated Proteins / metabolism
  • Nerve Degeneration / drug therapy
  • Nerve Degeneration / physiopathology
  • Nerve Degeneration / prevention & control
  • Neurogenesis / drug effects
  • Neurogenesis / physiology
  • Neuronal Plasticity / drug effects
  • Neuronal Plasticity / physiology
  • Neuropeptides / analysis
  • Neuropeptides / metabolism
  • Neuroprotective Agents / therapeutic use
  • Pyrroles / therapeutic use*
  • Rats
  • Rats, Wistar
  • Regeneration / drug effects
  • Regeneration / physiology
  • Simvastatin / therapeutic use*
  • Treatment Outcome

Substances

  • Biomarkers
  • Dcx protein, rat
  • Doublecortin Domain Proteins
  • Doublecortin Protein
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Microtubule-Associated Proteins
  • Neuropeptides
  • Neuroprotective Agents
  • Pyrroles
  • Atorvastatin
  • Simvastatin
  • Bromodeoxyuridine